- Home
- TEAF vs INBX Comparison
TEAF vs INBX Comparison
Compare TEAF & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- INBX
- Stock Information
- Founded
- TEAF 2017
- INBX 2010
- Country
- TEAF United States
- INBX United States
- Employees
- TEAF N/A
- INBX N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- INBX Health Care
- Exchange
- TEAF Nasdaq
- INBX Nasdaq
- Market Cap
- TEAF 165.2M
- INBX 237.5M
- IPO Year
- TEAF N/A
- INBX 2020
- Fundamental
- Price
- TEAF $12.83
- INBX $17.43
- Analyst Decision
- TEAF
- INBX Hold
- Analyst Count
- TEAF 0
- INBX 1
- Target Price
- TEAF N/A
- INBX N/A
- AVG Volume (30 Days)
- TEAF 56.1K
- INBX 117.9K
- Earning Date
- TEAF 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- TEAF 9.20%
- INBX N/A
- EPS Growth
- TEAF N/A
- INBX N/A
- EPS
- TEAF N/A
- INBX 118.83
- Revenue
- TEAF N/A
- INBX $1,687,000.00
- Revenue This Year
- TEAF N/A
- INBX N/A
- Revenue Next Year
- TEAF N/A
- INBX N/A
- P/E Ratio
- TEAF N/A
- INBX $0.14
- Revenue Growth
- TEAF N/A
- INBX 24.26
- 52 Week Low
- TEAF $11.11
- INBX $10.80
- 52 Week High
- TEAF $13.30
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- TEAF 67.79
- INBX 74.24
- Support Level
- TEAF $12.67
- INBX $14.51
- Resistance Level
- TEAF $13.00
- INBX $17.74
- Average True Range (ATR)
- TEAF 0.12
- INBX 0.81
- MACD
- TEAF 0.04
- INBX 0.26
- Stochastic Oscillator
- TEAF 81.75
- INBX 92.84
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.